As Anthem withdraws, tremor in foundations of Obamacare

22 June 2017

Anthem is pulling out of health insurance exchanges in Wisconsin and Indiana, a decision cheered by Republicans as another harbinger of doom for Obamacare.

The move, which follows healthcare giant Humana’s complete withdrawal of plans from state exchanges earlier in the year, strikes at the core of the Affordable Care Act, threatening to undermine one of its key provisions.

However, it’s not as bad as it could have been for supporters of the legislation. Anthem, which currently has over 800,000 members enrolled through exchanges in 14 states, was rumored to be exiting the program more comprehensively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK